Therapy Areas: Respiratory
US Merck Highlights New Data from Lung Cancer Clinical Development Programme at the IASLC 2019 World Conference on Lung Cancer
26 August 2019 - - New data from US-based Merck's (NYSE: MRK) clinical development programme in lung cancer will be presented at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Barcelona, Spain from Sept. 7-10, 2019.

More than 30 abstracts evaluating Keytruda, Merck's anti-PD-1 therapy, in combination with other cancer therapies and as monotherapy, will be presented.

Key data to be presented in non-small cell lung cancer (NSCLC) include new pooled findings from three trials KEYNOTE-189, KEYNOTE-407 and KEYNOTE-021 (cohort G), evaluating Keytruda in combination with chemotherapy among a subgroup of patients whose tumors do not express PD-L1.

Three-year overall survival data with Keytruda monotherapy from KEYNOTE-024 will also be presented and was selected for inclusion in the official WCLC press programme.
Login
Username:

Password: